Regeneron's rare immune disorder therapy meets main goal of late-stage trial

R

Regeneron's rare immune disorder therapy meets main goal of late-stage trial Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday its experimental therapy significantly improved daily activities...